Revorf

Revorf is a Japanese biotechnology venture established in November 2019 by Shinichi Sueta, a clinical physician. The company focuses on the fields of infectious and autoimmune diseases, combining information analysis with proprietary bio-technology to develop its testing, drug discovery, and drug discovery support businesses.

The company's core technology is based on the "Neoself Theory," a new mechanism explaining the root of autoimmune diseases. Leveraging this, Revorf has developed and is concentrating on the "β2GPI Neoself Antibody Test," a novel blood test for infertility and recurrent miscarriage. This test identifies neoself-antibodies, which are linked to about 20% of miscarriage cases and have also been associated with infertility. Clinical studies have shown that for patients who test positive and receive corresponding treatment, the pregnancy rate more than doubled in infertility cases, and the live birth rate increased by approximately 1.7 times in recurrent miscarriage cases. Since starting the testing business in 2022, Revorf has deployed it to over 150 medical institutions across Japan.

In addition to diagnostics, Revorf is engaged in drug discovery and support, utilizing advanced computational processing of biological information. A key area is allosteric drug discovery, which is being developed in partnership with Toshiba Digital Solutions, using their quantum-inspired optimization solution, SQBM+™. This collaboration aims to identify new drug targets on proteins previously considered undruggable.

Revorf has secured approximately 300 million JPY in funding from investors including Sumitomo Corporation, Toshiba Digital Solutions, and several venture capital firms. Sumitomo Corporation has also partnered with Revorf as the exclusive overseas distributor for its infertility and miscarriage testing business, aiming to address declining birth rates globally. The company operates its headquarters in Tokyo and a testing center at Osaka University. On January 6, 2025, Revorf announced it was changing its name to AOI Biosciences Co., Ltd.

Keywords: biotechnology, autoimmune disease, infertility testing, recurrent miscarriage, drug discovery, diagnostics, neoself theory, β2GPI neoself antibody test, allosteric drug discovery, quantum computing in pharma, medical technology, life sciences, clinical physician founder, Japanese biotech